非裔美国人、肾脏疾病与药物开发:监管视角
本文从监管角度讨论非裔美国人肾脏疾病负担重,需开发安全有效产品延缓进展;指出该人群治疗反应存在差异且历史临床试验代表性不足,APOL1风险变异发现为基因指导治疗和富集试验人群提供可能。
要点
- 非裔美国人肾脏疾病负担重,亟需延缓进展和降低肾衰竭风险的产品。
- 该人群治疗反应存在差异,临床试验代表性不足问题正被关注。
- APOL1风险变异发现提示可用遗传信息指导治疗或富集试验人群。
核心结论
- 开发延缓非裔美国人肾脏疾病进展和降低肾衰竭风险的产品意义重大。
- APOL1风险变异发现为靶向治疗和试验人群富集提供可能。
研究设计与样本
- 本文为监管视角的综述性文章,未报告系统检索范围或样本量。
主要发现
- 非裔美国人中观察到治疗反应差异,凸显在该人群中研究医疗产品的重要性。
- 非裔美国人社区历史上在临床试验中代表性不足,但已有努力在解决该问题。
- 对疾病进展遗传贡献的认识进展包括发现载脂蛋白L1基因(APOL1)风险变异。
临床怎么用
- 关注非裔美国人肾脏疾病治疗反应差异,重视该人群的临床研究证据。
- 可考虑利用APOL1风险变异信息指导治疗开发或富集高风险试验人群。
局限性
- 本文为监管视角综述,未报告具体研究设计、样本量或定量结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the burden of kidney disease in African Americans, the discovery of safe and effective medical products to slow the progression of kidney disease and reduce the risk for kidney failure would have a tremendous impact on this population. Differences in response to treatment have been observed in African Americans, highlighting the importance of studying medical products in African Americans. Although historically the African American community has not been well represented in clinical trials, efforts are underway to address this issue. Recent advances in understanding the genetic contributions to disease progression in African Americans, including the discovery of risk variants in the apolipoprotein L1 gene (APOL1), raise the possibility of using genetic information to better tailor treatments for African Americans. One could envision developing therapies that target these variants or possibly using them to help enrich trial populations with patients more likely to experience disease progression.
引用
- Panico C, Thompson A. African Americans, Kidney Disease, and Drug Development: A Regulatory Perspective. Am J Kidney Dis. 2018. PMID: 30343721. doi:10.1053/j.ajkd.2018.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。